BioRestorative Therapies Extends CEO, CFO Contracts Amid Going Concern & Activist Pressure
BRTX has more than doubled off its 52-week low of $0.159.
Summary
BioRestorative Therapies extended the employment agreements for CEO Lance Alstodt and CFO Robert Kristal through May 27, 2029, with their current salaries remaining unchanged. This decision comes after the company's recent 10-Q filing on May 14th, which detailed a going concern warning and Nasdaq delisting risk, alongside a plan to significantly increase authorized shares. The extension also follows an activist hedge fund, Kaos Capital, acquiring a 4.9% stake on May 27th and urgently seeking a meeting with management. Extending current leadership's contracts amidst severe financial distress and activist pressure signals continuity of the existing management team. The outcome of Kaos Capital's requested meeting will be important to watch.
At the time of this announcement, BRTX was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $0.16 to $2.05. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.